Red X iconGreen tick iconYellow tick icon

Contact Details

Email
peter.ganly@cdhb.health.nz
Position
Clinical Senior Lecturer
Department
Department of Pathology and Biomedical Science (Christchurch)
Qualifications
BM BCh(Oxford) MA PhD(Cambridge) FRACP FRCPA
Research summary
Cancer

Research

Dr Ganly's expertise and interests include the diagnosis and management of malignant haematological diseases, stem cell transplantation and clinical research.

Publications

Brown, J. R., Eichhorst, B., Hillmen, P., Jurczak, W., Kaźmierczak, M., Lamanna, N., … Ganly, P. S., Weinkove, R., … Shadman, M. (2024). Plain language summary of zanubrutinib or ibrutinib in chronic lymphocytic leukemia that is resistant to treatment or has come back after trreatment. Future Oncology, 20(12), 717-726. doi: 10.2217/fon-2023-0849 Journal - Research Article

Brown, J. R., Eichhorst, B., Lamanna, N., O'Brien, S., Tam, C. S., Qiu, L., … Ganly, P. S., Weinkove, R., … Shadman, M. (2024). Sustained benefit of zanubrutinib vs ibrutinib in patients with R/R CLL/SLL: Final comparative analysis of ALPINE. Blood. Advance online publication. doi: 10.1182/blood.2024024667 Journal - Research Article

Hungria, V., Robak, P., Hus, M., Zherebtsova, V., Ward, C., Ho, P. J., … Ganly, P., … for the DREAMM-7 Investigators, including George, A. (2024). Belantamab mofodotin, bortezomib, and dexamethasone for multiple myeloma. New England Journal of Medicine, 391(5), 393-407. doi: 10.1056/NEJMoa2405090 Journal - Research Article

Zinzani, P. L., Mayer, J., Flowers, C. R., Bijou, F., De Oliveira, A. C., Song, Y., … Ganly, P., … Trotman, J. (2023). ROSEWOOD: A phase II randomized study of zanubrutinib plus obinutuzumab versus obinutuzumab monotherapy in patients with relapsed or refractory follicular lymphoma. Journal of Clinical Oncology, 41(33), 5107-5117. doi: 10.1200/JCO.23.00775 Journal - Research Article

Hillmen, P., Eichhorst, B., Brown, J. R., Lamanna, N., O'Brien, S. M., Tam, C. S., … Ganly, P. S., Weinkove, R., … Jurczak, W. (2023). Zanubrutinib versus ibrutinib in relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma: Interim analysis of a randomised phase III trial. Journal of Clinical Oncology, 41(5), 1035-1045. doi: 10.1200/JCO.22.00510 Journal - Research Article

Back to top